350 related articles for article (PubMed ID: 36677670)
41. Novel Aceclofenac Cocrystals with l-Cystine: Virtual Coformer Screening, Mechanochemical Synthesis, and Physicochemical Investigations.
Kumar S; Gupta A; Prasad R; Singh S
Curr Drug Deliv; 2021; 18(1):88-100. PubMed ID: 32807053
[TBL] [Abstract][Full Text] [Related]
42. Novel Aceclofenac-l-Cystine and Aceclofenac-Urea Cocrystals with Enhanced Oral Bioavailability.
Kumar S; Gupta A; Mishra CK; Singh S
Curr Drug Deliv; 2021; 18(8):1174-1181. PubMed ID: 33602085
[TBL] [Abstract][Full Text] [Related]
43. Diffusion and Flux Improvement of Drugs through Complexation.
Mannava MKC; Garai A; Nangia AK
Mol Pharm; 2023 May; 20(5):2293-2316. PubMed ID: 36974968
[TBL] [Abstract][Full Text] [Related]
44. Pharmaceutical salts/cocrystals of enoxacin with dicarboxylic acids: Enhancing in vitro antibacterial activity of enoxacin by improving the solubility and permeability.
Liu L; Zou D; Zhang Y; Zhang Q; Feng Y; Guo Y; Liu Y; Zhang X; Cheng G; Wang C; Zhang Y; Zhang L; Wu L; Chang L; Su X; Duan Y; Zhang Y; Liu M
Eur J Pharm Biopharm; 2020 Sep; 154():62-73. PubMed ID: 32645384
[TBL] [Abstract][Full Text] [Related]
45. Bioavailability of indomethacin-saccharin cocrystals.
Jung MS; Kim JS; Kim MS; Alhalaweh A; Cho W; Hwang SJ; Velaga SP
J Pharm Pharmacol; 2010 Nov; 62(11):1560-8. PubMed ID: 21039541
[TBL] [Abstract][Full Text] [Related]
46. Crystal structures, dissolution and pharmacokinetic study on a novel phosphodiesterase-4 inhibitor chlorbipram cocrystals.
Zhou J; Li L; Zhang H; Xu J; Huang D; Gong N; Han W; Yang X; Zhou Z
Int J Pharm; 2020 Feb; 576():118984. PubMed ID: 31870960
[TBL] [Abstract][Full Text] [Related]
47. Crystal engineering to improve physicochemical properties of mefloquine hydrochloride.
Yadav AV; Dabke AP; Shete AS
Drug Dev Ind Pharm; 2010 Sep; 36(9):1036-45. PubMed ID: 20334542
[TBL] [Abstract][Full Text] [Related]
48. Optimizing Drug Development: Harnessing the Sustainability of Pharmaceutical Cocrystals.
Aitipamula S; Bolla G
Mol Pharm; 2024 Jul; 21(7):3121-3143. PubMed ID: 38814314
[TBL] [Abstract][Full Text] [Related]
49. Solid state manipulation of lornoxicam for cocrystals--physicochemical characterization.
Nijhawan M; Santhosh A; Babu PR; Subrahmanyam CV
Drug Dev Ind Pharm; 2014 Sep; 40(9):1163-72. PubMed ID: 23829186
[TBL] [Abstract][Full Text] [Related]
50. Influence of Coformer Stoichiometric Ratio on Pharmaceutical Cocrystal Dissolution: Three Cocrystals of Carbamazepine/4-Aminobenzoic Acid.
Li Z; Matzger AJ
Mol Pharm; 2016 Mar; 13(3):990-5. PubMed ID: 26837376
[TBL] [Abstract][Full Text] [Related]
51. Recent advances in improving oral drug bioavailability by cocrystals.
Emami S; Siahi-Shadbad M; Adibkia K; Barzegar-Jalali M
Bioimpacts; 2018; 8(4):305-320. PubMed ID: 30397585
[No Abstract] [Full Text] [Related]
52. The mechanism of binding with the α-glucosidase in vitro and the evaluation on hypoglycemic effect in vivo: Cocrystals involving synergism of gallic acid and conformer.
Xue N; He B; Jia Y; Yang C; Wang J; Li M
Eur J Pharm Biopharm; 2020 Nov; 156():64-74. PubMed ID: 32890659
[TBL] [Abstract][Full Text] [Related]
53. Coamorphous Active Pharmaceutical Ingredient-Small Molecule Mixtures: Considerations in the Choice of Coformers for Enhancing Dissolution and Oral Bioavailability.
Newman A; Reutzel-Edens SM; Zografi G
J Pharm Sci; 2018 Jan; 107(1):5-17. PubMed ID: 28989014
[TBL] [Abstract][Full Text] [Related]
54. Obtaining Cocrystals by Reaction Crystallization Method: Pharmaceutical Applications.
Biscaia IFB; Gomes SN; Bernardi LS; Oliveira PR
Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34204318
[TBL] [Abstract][Full Text] [Related]
55. Automatic Cocrystal Detection by Raman Spectral Deconvolution-Based Novelty Analysis.
Yaghoobi M; Grecu T; Brookes S; Campbell CJ
Anal Chem; 2021 Nov; 93(43):14375-14382. PubMed ID: 34677947
[TBL] [Abstract][Full Text] [Related]
56. Creation of Hydrochlorothiazide Pharmaceutical Cocrystals Via Hot-Melt Extrusion for Enhanced Solubility and Permeability.
Narala S; Nyavanandi D; Alzahrani A; Bandari S; Zhang F; Repka MA
AAPS PharmSciTech; 2022 Jan; 23(1):56. PubMed ID: 35043282
[TBL] [Abstract][Full Text] [Related]
57. Engineering and manufacturing of pharmaceutical co-crystals: a review of solvent-free manufacturing technologies.
Ross SA; Lamprou DA; Douroumis D
Chem Commun (Camb); 2016 Jul; 52(57):8772-86. PubMed ID: 27302311
[TBL] [Abstract][Full Text] [Related]
58. Daidzein cocrystals: An opportunity to improve its biopharmaceutical parameters.
Bhalla Y; Chadha K; Chadha R; Karan M
Heliyon; 2019 Nov; 5(11):e02669. PubMed ID: 31763466
[TBL] [Abstract][Full Text] [Related]
59. Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals.
Healy AM; Worku ZA; Kumar D; Madi AM
Adv Drug Deliv Rev; 2017 Aug; 117():25-46. PubMed ID: 28342786
[TBL] [Abstract][Full Text] [Related]
60. Pharmaceutical cocrystals: walking the talk.
Bolla G; Nangia A
Chem Commun (Camb); 2016 Jun; 52(54):8342-60. PubMed ID: 27278109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
